NCT04750252View on ClinicalTrials.gov

Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Osteo Arthritis Knee
Interventions
BIOLOGICAL

StroMel

Autologous MSC

Trial Locations (1)

20879

Mukesh, Gaithersburg

Sponsors
All Listed Sponsors
lead

Akan Biosciences, LLC

INDUSTRY

NCT04750252 - Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint | Biotech Hunter | Biotech Hunter